{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=29", "query": { "intervention": "Combination 400", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 1062, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T11:52:54.474Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06129734", "title": "Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloid Malignancy", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Benjamin Tomlinson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-07-28", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-11-06T11:52:54.474Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06129734" }, { "nct_id": "NCT00906373", "title": "A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)", "type": "BIOLOGICAL" }, { "name": "IMC-A12 (cixutumumab) - 20 mg/kg", "type": "BIOLOGICAL" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2009-05", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2018-06-04", "last_synced_at": "2026-11-06T11:52:54.474Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Chicago, Illinois + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Burlington", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00906373" }, { "nct_id": "NCT01653470", "title": "Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "5-Fluorouracil (5FU)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "BMS-906024", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 141, "start_date": "2012-10-12", "completion_date": "2017-05-08", "has_results": false, "last_update_posted_date": "2020-01-28", "last_synced_at": "2026-11-06T11:52:54.474Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01653470" }, { "nct_id": "NCT01183780", "title": "A Study in Second Line Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Ramucirumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Folinic Acid", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1072, "start_date": "2010-12-02", "completion_date": "2016-06-20", "has_results": true, "last_update_posted_date": "2019-09-25", "last_synced_at": "2026-11-06T11:52:54.474Z", "location_count": 92, "location_summary": "Sedona, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 89 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183780" }, { "nct_id": "NCT00612586", "title": "Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Enzastaurin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Leucovorin (LV)", "type": "DRUG" }, { "name": "5-fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Bevacizumab (Bev)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2008-02", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2020-07-21", "last_synced_at": "2026-11-06T11:52:54.474Z", "location_count": 3, "location_summary": "Memphis, Tennessee • Houston, Texas • Salt Lake City, Utah", "locations": [ { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612586" }, { "nct_id": "NCT01565850", "title": "D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "D/C/F/TAF", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "D/C/F/TAF Placebo", "type": "DRUG" }, { "name": "DRV Placebo", "type": "DRUG" }, { "name": "COBI Placebo", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2012-04", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2016-04-11", "last_synced_at": "2026-11-06T11:52:54.474Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01565850" }, { "nct_id": "NCT04274738", "title": "A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Waldenstrom's Macroglobulinemia" ], "interventions": [ { "name": "Mavorixafor", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "X4 Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-04-30", "completion_date": "2022-10-31", "has_results": false, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-11-06T11:52:54.474Z", "location_count": 4, "location_summary": "Denver, Colorado • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04274738" }, { "nct_id": "NCT04812535", "title": "Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "SCC - Squamous Cell Carcinoma of Skin" ], "interventions": [ { "name": "Vilobelimab", "type": "DRUG" }, { "name": "Vilobelimab + pembrolizumab combination therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InflaRx GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-03-31", "completion_date": "2024-06-04", "has_results": true, "last_update_posted_date": "2025-02-11", "last_synced_at": "2026-11-06T11:52:54.474Z", "location_count": 6, "location_summary": "La Jolla, California • Aurora, Colorado • Miami, Florida + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04812535" }, { "nct_id": "NCT00463840", "title": "Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5FU", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "FOLFOX 6", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2004-06", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-11-06T11:52:54.474Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00463840" }, { "nct_id": "NCT02386826", "title": "INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Gliosarcoma", "Colorectal Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "INC280", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-09-22", "completion_date": "2023-08-23", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-11-06T11:52:54.474Z", "location_count": 5, "location_summary": "Denver, Colorado • New Haven, Connecticut • Kansas City, Missouri + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02386826" } ] }